More tools:Markets·Screener·Research·Chat

Amgen Inc (AMGN) Financial Statements

Amgen Inc
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S5NNL6
XNAS · usd
393.17▼ 44.06 (-10.08%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close437.23
Day's Range391.17 – 410.03
52-Week Range269.77 – 447.03
Volume6.5M
Avg Volume2.6M
Share Statistics
Shares Outstanding
Employees31.5K
ExchangeXNAS
Listed1983-06-17
Share count as of July 30, 2026
Loading Income Statement…
Key questions about Amgen Inc (AMGN)
What is Amgen Inc's Market Cap?
Amgen Inc's Market Cap is $212.6B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Enterprise Value?
Amgen Inc's Enterprise Value is $255.9B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Trailing P/E?
Amgen Inc's Trailing P/E is 24.3×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Price / Sales?
Amgen Inc's Price / Sales is 5.6×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / Revenue?
Amgen Inc's EV / Revenue is 6.7×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EV / EBITDA?
Amgen Inc's EV / EBITDA is 17.4×, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Revenue (TTM)?
Amgen Inc's Revenue (TTM) is $38.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Net Income (TTM)?
Amgen Inc's Net Income (TTM) is $8.7B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's EBITDA?
Amgen Inc's EBITDA is $16.1B, based on as-reported figures from SEC (XBRL) filings.
What is Amgen Inc's Diluted EPS (TTM)?
Amgen Inc's Diluted EPS (TTM) is 16.17, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+9.5%+5.8%+8.6%+12.4%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Other
Total operating expenses
% of revenue65.0%69.1%72.4%73.6%
Operating income
% of revenue35.0%30.9%27.6%26.4%
Other income (expense):
Interest expense, net
Other (expense) income, net
Income before income taxes
Provision for income taxes
Net income
% of revenue23.6%21.1%13.5%33.7%
Basic (in usd per share)
Diluted (in usd per share)